Exhibit 99.1 Ocugen Provides Business Update with Third Quarter 2025 Financial Results Conference Call and Webcast Today at 8:30 a.m. ET MALVERN, Pa., November 5, 2025 (GLOBE NEWSWIRE) – Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today reported third quarter 2025 financial results along with a general business update. "With two late-stage modifier gene therapies on track to meet 2026 and 2027 BLA/MAA filings, it's rema ...